Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines

International Journal of Cancer

Volumn 104, Issue 2, 2003, Pages 238-242

  Tsurutani, Junji ^a,b   Soda, Hiroshi ^a,b   Oka, Mikio ^a,b   Suenaga, Mitsuhiro ^a   Doi, Seiji ^a   Nakamura, Yoichi ^a   Nakatomi, Katsumi ^a   Shiozawa, Ken ^a   Yamada, Yasuaki ^b   Kamihira, Shimeru ^b   Kohno, Shigeru ^a,b  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Grad Sch Biomed Sci   (Japan)

Author keywords

Apoptosis; Drug resistance; Histone deacetylase inhibitor; Lung cancer; Telomerase

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; CYCLOHEXIMIDE; ETOPOSIDE; FR 901228; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CROSS RESISTANCE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; APOPTOSIS; CARCINOMA, SMALL CELL; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DEPSIPEPTIDES; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HISTONE DEACETYLASES; HUMANS; LUNG NEOPLASMS; PEPTIDES, CYCLIC; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; TELOMERASE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0037457316     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10921     Document Type: Article

References (29)

1. Shepherd FA. Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer. Semin Oncol 2001;28:30-7.
2. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994;47:301-10.
3. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994;47:315-23.
4. Kosugi H, Ito M, Yamamoto Y, Towatari M, Ito M, Ueda R, Saito H, Naoe T. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice. Jpn J Cancer Res 2001;92:529-36.
5. Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, et al. Sequential 5-aza-2-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-EOS-1. J Immunother 2001;24:151-61.
6. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-13.
7. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE. Inhibition of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98: 2865-8.
8. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28.
9. Weidle UH, Grossmann A. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 2000;20:1471-86.
10. Suenaga M, Soda H, Oka M, Yamaguchi A, Nakatomi K, Shiozawa K, Kawabata S, Kasai T, Yamada Y, Kamihira S, Tei C, Kohno S. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. Int J Cancer 2002;97: 621-5.
11. Dhaene K, Van Marck E, Parwaresch R. Telomeres, telomerase and cancer: an up-date. Virchow Arch 2000;437:1-16.
12. Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, Piatyszek MA, Shay JW. Telomerase activity in small-cell and nonsmall-cell lung cancers. J Natl Cancer Inst 1995;87:895-902.
13. Doyle LA, Ross DD, Ordonez JV, Yang W, Gao Y, Tong Y, Belani CP, Gutheil JC. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein. Br J Cancer 1995; 72:535-42.
14. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophy Res Co 2001;280: 1216-23.
15. 1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000;83:817-25.
16. Ducrest A-L, Szutorisz H, Lingner J, Nabholz M. Regulation of the human telomerase reverse transcriptase gene. Oncogene 2002;21: 541-52.
17. Kitazono M, Goldsmith ME, Aikou T, Bates S, Fojo T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res 2001;61:6328-30.
18. WAFI expression and gene-associated histone acetylation. Proc Natl Acad Sci 2000;97:10014-9.
19. WAFI/CIPI by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 2000;60:828-37.
20. Fecteau KA, Mei J, Wang HCR. Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228. J Pharmacol Exp Ther 2002;300:890-9.
21. Blagosklonny M, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002;1:937-41.
22. 2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000;11:2069-83.
23. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 1996;16:2932-9.
24. Faraoni I, Turriziani M, Masci G, De Vecchis L, Shay JW, Bonmassar E, Graziani G. Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin Cancer Res 1997; 3:579-85.
25. Mergny J-L, Riou J-F, Mailliet P, Teulade-Fichou M-P, Gilson E. Natural and pharmacological regulation of telomerase. Nucleic Acids Res 2002;30:839-65.
26. Cao Y, Li H, Deb S, Liu J-P. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 2002;21:3130-8.
27. Gomez-Roman JJ, Romero AF, Castro LS, Nieto EH, Fernandez-Luna JL, Val-Bernal JF. Telomerase activity in pulmonary neuroendocrine tumors: correlation with histologic subtype (MS-0060). Am J Surg Pathol 2000;24:417-21.
28. Marchetti A, Bertacca G, Buttitta F, Chella A, Quattrocolo G, Angeletti CA, Bevilacqua G. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res 1999;5: 2077-81.
29. Gonzalez-Quevedo R, Iniesta P, Moran A, de Juan C, Sanchez-Pernaute A, Fernandez C, Torres A, Diaz-Rubio E, Balibrea JL, Benito M. Cooperative role of telomerase activity and p16 expression in the prognosis of non-small-cell lung cancer. J Clin Oncol 2001;20: 254-62.